

Not for release to US wire services or distribution in the United States

Placement of Entitlement Offer Shortfall

On 31 October 2023, Radiopharm Theranostics Limited (ASX:RAD) (**Radiopharm** or **Company**) announced the details of a non-renounceable entitlement offer (**Entitlement Offer**) to raise approximately \$10 million. Under the Entitlement Offer, eligible shareholders were able to subscribe for 1 new fully paid ordinary share in Radiopharm (**New Shares**) for every 2.35 fully paid ordinary shares in Radiopharm at the issue price of \$0.07 per New Share. Radiopharm received valid applications under the Entitlement Offer for 30,197,244 New Shares, raising an amount of approximately \$2.1 million.

Radiopharm is pleased to advise it has received commitments totalling approximately A\$1.7 million for the Shortfall under the Entitlement Offer. The 24,025,716 New Shares will be issued at the same price per share as the Entitlement Offer being \$0.07 per New Share and will rank equally in all respects with existing shares on issue. Funds will be used to support the company's clinical programs.

Radiopharm CEO Riccardo Canevari said, "We would like to thank our existing and incoming investors for their support of our programs, our pipeline and our team."

Indicative timetable

Event	Sydney, Australia Time
Placement announced on the ASX	Wednesday, 24 January 2024
Settlement of Placement Shares	Tuesday, 30 January 2024
Allotment of Placement Shares	Wednesday, 31 January 2024

Note: This timetable is indicative only and subject to change. The Company reserves the right to vary the above dates and times, subject to the ASX Listing Rules and the Corporations Act.

Not an offer in the United States

This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws.

About Radiopharm Theranostics

Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm has been listed on ASX (RAD) since November 2021. The company has a pipeline of six distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development from some of the world's leading universities and institutes. The pipeline has been built based on the potential to be first-to-market or best-in-class. The clinical program includes one Phase II and three Phase I trials in a variety of solid tumour cancers including breast, kidney and brain. Learn more at [Radiopharmtheranostics.com](https://radiopharmtheranostics.com).

Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper.

For more information:

Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com

Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au

Follow Radiopharm Theranostics:

Website – <https://radiopharmtheranostics.com/>
Twitter – <https://twitter.com/TeamRadiopharm>
Linked In – <https://www.linkedin.com/company/radiopharm-theranostics/>
InvestorHub – <https://investorhub.radiopharmtheranostics.com/>

